USA – Kriya Therapeutics, Inc., a Redwood City, CA and Research Triangle Park, NC-based fully integrated gene therapy company advancing novel technologies and therapeutics, raised $270m in Series C financing.
The round was led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors. The company intends to use the funds for the advancement of its pipeline and continued scaling of its engineering, manufacturing, and computational platforms.Led by Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer, Kriya has established an ecosystem for delivering technologies and medicines in gene therapy, with core business units in technology, manufacturing, R&D, and therapeutics. By leveraging its proprietary computational platform, in-house manufacturing infrastructure, and rational design toolkit, the company is positioned to bring potentially transformative gene therapies to a broad range of diseases.In recent months, Kriya has achieved several milestones across key parts of its business. The company significantly expanded its pipeline through its internal R&D efforts, as well as through acquisitions and partnerships with leading companies and academic institutions. In addition, Kriya operationalized its scalable GMP manufacturing infrastructure in Research Triangle Park, North Carolina to support in-house production from early through late phase development. This infrastructure also empowers the development and implementation of novel technologies and processes that enable consistent, large-scale manufacturing. Kriya has also scaled SIRVE™, its machine learning-enabled technology and cloud computing architecture, to support the integration of large datasets generated by the company’s high throughput screening, next generation sequencing, and algorithmic data mining platforms.17/05/2022
